Loading...
Zanidatamab, a bispecific antibody targeting two epitopes of HER2, was developed to have stronger anti-HER2 activity and immune activation than trastuzumab for treating solid tumors. Now, in the industry-funded, phase 3 HERIZON-GEA-01 trial, researchers randomized 914 patients with previously untreated HER2+ gastroesophageal adenocarcinoma to one of three open-label regimens: zanidatamab–chemotherapy; zanidatamab–tislelizumab (immunotherapy)–chemotherapy; or trastuzumab–chemotherapy. Median follow-up was 26 months (a first interim analysis).
Median progression-free survival was significantly longer with both zanidatamab-containing regimens (12.4 months for each) than with trastuzumab–chemotherapy (8.1 months).
Median overall…